Biogen's Phase 2 CELIA Trial Fails, Investigation Launched

What happened

Biogen shares fell 6.4% after Phase 2 topline data for diranersen (CELIA) missed its primary dose-response endpoint, a setback for the rare disease pipeline. The miss raises questions about the company's ability to offset multiple sclerosis revenue erosion with newer launches, though diranersen was a relatively small program. Levi & Korsinsky initiated an investigation into Biogen's officers and directors, alleging that material information was omitted from filings, introducing legal overhang. The news comes as Biogen trades near its 52-week high after a strong run in 2025, leaving the stock vulnerable to negative catalysts. While the failed trial does not affect core growth drivers like Leqembi and Skyclarys, it adds to the narrative of pipeline execution risk and may pressure sentiment.

Implication

The 6.4% selloff reflects the market's sensitivity to pipeline failures, but the CELIA program was not a key value driver in the DeepValue analysis. The investigation adds legal risk and could distract management, but its materiality is uncertain. Near term, the stock may trade lower as the market digests this news, especially after a strong run-up. The base case $185 target requires continued execution from Leqembi and Skyclarys; this event does not fundamentally break that thesis. However, it increases the probability of the bear case ($160) if it signals broader pipeline weakness or further negative surprises. Investors should monitor for any additional pipeline disappointments in upcoming quarters.

Thesis delta

The failed CELIA trial and investigation do not alter the core investment thesis, which rests on Leqembi and rare disease growth offsetting MS decline. However, they add to the list of execution risks and could dampen near-term sentiment, potentially delaying the stock's path to the base case. The probability of the bear case has increased modestly, but we maintain our WAIT rating until more clarity on 2026 guidance and Leqembi adoption emerges.